Comparative structure-function studies with analogs of dynorphin-(1-13) and [Leu5]enkephalin.
Analogs of dynorphin-(1-13) with modifications in the enkephalin segment were compared with correspondingly modified analogs of [Leu5]enkephalin in the guinea pig ileum (GPI) and mouse vas deferens (MVD) assay as well as in mu- and delta-receptor selective binding assays. The obtained results indicate that a) the enkephalin binding domain of the dynorphin (kappa) receptor has structural requirements which are distinct from those of the enkephalin binding site at the mu-receptor and b) the introduction of an identical conformational constraint in [Leu5]enkephalin and in the enkephalin segment of dynorphin-(1-13) produces a superpotent agonist in both cases. Fluorescence energy transfer measurements with the active [4-tryptophan]analogs of dynorphin-(1-13) and [Leu5]enkephalin and with dynorphin-(1-17) demonstrated a more extended conformation of the N-terminal tetrapeptide segment in [Trp4]dynorphin-(1-13) than in [Trp4, Leu5]enkephalin as well as the absence of an interaction between the N- and C-terminal segments of dynorphin-(1-17).
D000818:Animals; D001921:Brain / Q000378:metabolism; D004399:Dynorphins; D004723:Endorphins; D004743:Enkephalin, Leucine / Q000031:analogs & derivatives*; D006168:Guinea Pigs; D007082:Ileum / Q000378:metabolism; D008297:Male; D051379:Mice; D051381:Rats; D013329:Structure-Activity Relationship; D014649:Vas Deferens / Q000378:metabolism
D004723:Endorphins; D004743:Enkephalin, Leucine; D004399:Dynorphins